Corticotropin-releasing factor receptor antagonists

Bibliography

• NEMEROFF CB, OWENS MJ: Treatment of mood disorders. Nat. Neurosci. (2002) 5(Suppl.):1068-1070.
   PubMed Web of Science ®Google Scholar
• WONG ML, LICINIO J: Research and treatment approaches to depression. Nat. Rev. Neurosci. (2001) 2:343-351.
   PubMed Web of Science ®Google Scholar
• LANIER M, WILLIAMS JP: Small molecule corticotropin releasing factor antagonists. Expert Opin. Ther. Patents (2002) 12:1619-1630.
   Web of Science ®Google Scholar
• GILLIGAN PJ, ROBERTSON DW, ZACZEK R: Corticotropin releasing factor (CRF) receptor modulators: progress and opportunities for new therapeutic agents. J. Med. Chem. (2000) 43:1641-1660.
   PubMed Web of Science ®Google Scholar
• OWENS MJ, NEMEROFF CB: Physiology and pharmacology of corticotropin releasing factor. Pharmacol. Rev. (1991) 43:425-473.
   PubMed Web of Science ®Google Scholar
• BALE TL, VALE WV: CRF and CRF receptors: role in stress responsivity and other behaviors. Annu. Rev. Pharmacol. Toxicol. (2004) 44:525-557.
   PubMed Web of Science ®Google Scholar
• DAUTZENBERG FM, HAUGER RL: The CRF peptide family and their receptors: yet more partners discovered. Trends Pharm. Sci. (2002) 23:71-77.
   PubMed Web of Science ®Google Scholar
• RUHMANN A, BONK I, LIN CJR et al.: Structural requirements for peptidic antagonists of the corticotropin-releasing factor receptor (CRFR): development of CRFR2 β-selective antisauvagine-30. Proc. Natl. Acad. Sci. USA (1998) 95:15264-15269.
   PubMed Web of Science ®Google Scholar
• ZOBEL AW, NICKEL T, KUNZEL HE et al.: Effects of the high affinity corticotropin releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J. Psychiatric Res. (2000) 34:171-181.
   PubMed Web of Science ®Google Scholar
• ECKART K, JAHN O, RADULOVIC J et al.: A single amino acid serves as an affinity switch between the receptor and the binding protein of corticotropin-releasing factor: implications for the design of agonists and antagonists. Proc. Natl. Acad. Sci. USA (2001) 98:11142-11146.
   PubMed Web of Science ®Google Scholar
• TODOROVIC C, JAHN O, TEZVAL H et al.: The role of CRF receptors in anxiety and depression: Implications of the novel CRF1 agonist cortagine. Neurosci. Biobehavioral Rev. (2005) 29:1323-1333.
   PubMed Web of Science ®Google Scholar
• ARVANITIS AG, GILLIGAN PJ, CHORVAT RJ et al.: Non-peptide corticotropin releasing hormone (CRH) antagonists: The syntheses and structure–activity relationships of 2-anilino-pyrimidines and -triazines. J. Med. Chem. (1999) 42:808-818.
   Google Scholar
• SCHULZ DW, MANSBACH RS, SPROUSE J et al.: CP-154526: a potent and selective nonpeptide antagonist of corticotropin releasing factor receptors. Proc. Natl. Acad. Sci. USA (1996) 93:10477-10482.
   PubMed Web of Science ®Google Scholar
• CHEN YL, MANBACH RS, WINTER SM et al.: Synthesis and efficacy of 4-(butylethylamino)pyrrolo [2,3-d]pyrimidine: a centrally active corticotropin releasing factor 1 receptor antagonist. J. Med. Chem. (1997) 40:1749-1754.
   PubMed Web of Science ®Google Scholar
• DUBOWCHIK GM, MICHNE JA, ZUEV D et al.: 2-Arylaminothiazoles as high affinity corticotropin-releasing factor 1 receptor (CRF1R) antagonists: synthesis, binding studies and behavioral efficacy. Bioorganic Med. Chem. Lett. (2003) 13:3997-4000.
   PubMed Web of Science ®Google Scholar
• HARTZ RA, NANDA KK, INGALLS CL et al.: Design, synthesis and biological evaluation of 1,2,3,7-tetrahydro-6H-purin-6-one and 3,7-dihydro-1H-purine-2,6-dione derivatives as corticotropin releasing factor1 receptor antagonists. J. Med. Chem. (2004) 47:4741-4754
   PubMed Web of Science ®Google Scholar
• DZIERBA CD, TAKVORIAN AG, RAFALSKI M et al.: Synthesis, structure-activity relationships and in vivo properties of 3,5-dihydro-1H-pyrido[2,3-b]pyrazin-2-ones as corticotropin-releasing factor-1 receptor antagonists. J. Med. Chem. (2004) 47:5783-5790.
   PubMed Web of Science ®Google Scholar
• HAN X, MICHNE JA, GAO Q et al.: Synthesis, structure–activity relationships and anxiolytic activity of 1-aryl-2,3-dihydroimidazoimidazole corticotropin releasing factor 1 receptor (CRF1R) antagonists. Bioorg. Med. Chem. Lett. (2005) 15:3870-3873.
   PubMed Web of Science ®Google Scholar
• HARTZ RA, NANDA KK, INGALLS CL: Synthesis of 2-amino-3-hydroxy-4-substituted pyridines via regioselective metalation of 3-(1-ethylpropyl)-[1,3]oxazolo[4,5-b]pyridin-2(3H)-one and application to corticotropin releasing factor1 receptor ligands. Tetrahedron Lett. (2005) 46:1683-1686.
   Web of Science ®Google Scholar
• DYCK B, GRIGORIADIS DE, GROSS RS et al.: Potent, orally active corticotropin-releasing factor receptor-1 antagonists containing tricyclic pyrrolopyridine or pyrazolopyridine core. J. Med. Chem. (2005) 48:4100-4110.
   PubMed Web of Science ®Google Scholar
• GUO Z, TELLEW JE, GROSS RS et al.: Design and synthesis of tricyclic imidazo[4,5-b]pyridin-2-ones as corticotropin-releasing factor-1 antagonists. J. Med. Chem. (2005) 48:5104-5107.
   PubMed Web of Science ®Google Scholar
• HAN X, PIN SS, BURRIS K et al.: Synthesis and structure–activity relationship of imidazo[1,2-a]benzimidazoles as corticotropin-releasing factor 1 receptor antagonists. Bioorganic Med. Chem. Lett. (2005) 15:4029-4032.
   PubMed Web of Science ®Google Scholar
• LOWE RF, NELSON J, DANG TN et al.: Rational design, synthesis and structure–activity relationships of aryltriazoles as novel corticotropin-releasing factor-1 receptor antagonists. J. Med. Chem. (2005) 48:1540-1549.
   PubMed Web of Science ®Google Scholar
• HODGETTS KJ, YOON T, HUANG J et al.: 2-Aryl-3,6-dialkyl-5-dialkylaminopyrimidin-4-ones as novel CRF-1 receptor antagonists. Bioorganic Med. Chem. Lett. (2003) 13:2497-2500.
   PubMed Web of Science ®Google Scholar
• SEYMOUR PA, SCHMIDT AW, SCHULZ, DW: The pharmacology of CP-154526-1, a non-peptide antagonist of the CRH1 receptor: a review. CNS Drug Rev. (2003) 9:57-96.
   PubMedGoogle Scholar
• GEMZIK B, SNYDER RD, BUNTON TE et al.: Thyrotropic effects of a pyrazolopyrimidine corticotropin releasing factor (CRFR1) receptor antagonist in rats. Toxicol. Sci. (2002) 66:abstract supplemental.
   Google Scholar
• WONG H, LEHMAN-MCKEEMAN LD, GRUBB MF et al.: Increased hepatobiliary clearance of unconjugated thyroxine determines DMP 904-induced alterations in thyroid hormone homeostasis in rats. Toxicol. Sci. (2005) 84:232-242.
   PubMed Web of Science ®Google Scholar